Ondřej Pelák1,2, Jan Stuchlý1,2, Ladislav Król1,2, Petr Hubáček1, Petra Keslová1, Petr Sedláček1, Renata Formánková1, Jan Starý1, Ondřej Hrušák1,2, Tomáš Kalina1,2. 1. Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University Prague and University Hospital Motol, V Uvalu 84, Prague, 150 06, Czech Republic. 2. CLIP-Childhood Leukemia Investigation Prague, 2nd Faculty of Medicine, Charles University Prague and University Hospital Motol, V Uvalu 84, Prague, 150 06, Czech Republic.
Abstract
BACKGROUND: Cytomegalovirus (CMV) specific T-cells are known to provide long-term control of CMV reactivation, which is a frequent complication of hematopoietic stem cell transplantation. We have studied 58 pediatric patients after hematopoietic stem cell transplantation who suffered from CMV reactivation to reveal which functional T cell subset is best correlating with successful reactivation resolution and which protects from reactivation episode. METHODS: Detection of 30 combinatorial subsets of four types of response to ex vivo CMV stimulation (IFNγ secretion, IL-2 secretion, CD40L upregulation and degranulation) that were detectable on either CD8+ or CD4+ T cells through flow cytometry intracellular cytokine staining was used. RESULTS: We found that the presence of CD8+ dual positive (IFNγ+ and IL-2+) cells is the most accurate functional parameter that can predict fast resolution of CMV reactivation. Next, we show that the presence of CD8+ dual positive (IFNγ+ and IL-2+) and CD8+ IFNγ+ cells provides a protective effect (a hazard risk of 0.28 (confidence interval 0.18 - 0.43) and 0.45 (CI 0.27 - 0.75), respectively) and the presence of corticotherapy increases the risk of reactivation (HR 2.47 (CI 1.82-3.36)). Thus, a patient without corticotherapy and with both of the critical T cell subsets present has a cumulative 19.6 times lower risk of developing CMV reactivation than a patient on corticotherapy and without CD8+ dual positive (IFNγ+ and IL-2+) or CD8+ IFNγ+ cells. CONCLUSIONS: We have established parameters of CMV specific functional response ex vivo that can be used in assisting clinical management of patients with CMV reactivation.
BACKGROUND: Cytomegalovirus (CMV) specific T-cells are known to provide long-term control of CMV reactivation, which is a frequent complication of hematopoietic stem cell transplantation. We have studied 58 pediatric patients after hematopoietic stem cell transplantation who suffered from CMV reactivation to reveal which functional T cell subset is best correlating with successful reactivation resolution and which protects from reactivation episode. METHODS: Detection of 30 combinatorial subsets of four types of response to ex vivo CMV stimulation (IFNγ secretion, IL-2 secretion, CD40L upregulation and degranulation) that were detectable on either CD8+ or CD4+ T cells through flow cytometry intracellular cytokine staining was used. RESULTS: We found that the presence of CD8+ dual positive (IFNγ+ and IL-2+) cells is the most accurate functional parameter that can predict fast resolution of CMV reactivation. Next, we show that the presence of CD8+ dual positive (IFNγ+ and IL-2+) and CD8+ IFNγ+ cells provides a protective effect (a hazard risk of 0.28 (confidence interval 0.18 - 0.43) and 0.45 (CI 0.27 - 0.75), respectively) and the presence of corticotherapy increases the risk of reactivation (HR 2.47 (CI 1.82-3.36)). Thus, a patient without corticotherapy and with both of the critical T cell subsets present has a cumulative 19.6 times lower risk of developing CMV reactivation than a patient on corticotherapy and without CD8+ dual positive (IFNγ+ and IL-2+) or CD8+ IFNγ+ cells. CONCLUSIONS: We have established parameters of CMV specific functional response ex vivo that can be used in assisting clinical management of patients with CMV reactivation.
Authors: Renata Formankova; Veronika Kanderova; Marketa Rackova; Michael Svaton; Tomas Brdicka; Petr Riha; Petra Keslova; Ester Mejstrikova; Marketa Zaliova; Tomas Freiberger; Hana Grombirikova; Zuzana Zemanova; Marcela Vlkova; Filip Fencl; Ivana Copova; Jiri Bronsky; Petr Jabandziev; Petr Sedlacek; Jana Soukalova; Ondrej Zapletal; Jan Stary; Jan Trka; Tomas Kalina; Karolina Skvarova Kramarzova; Eva Hlavackova; Jiri Litzman; Eva Fronkova Journal: Front Immunol Date: 2019-09-18 Impact factor: 7.561
Authors: Jan Havlin; Monika Svorcova; Eliska Dvorackova; Jan Lastovicka; Robert Lischke; Tomas Kalina; Petr Hubacek Journal: J Heart Lung Transplant Date: 2021-05-21 Impact factor: 10.247